scholarly article | Q13442814 |
P356 | DOI | 10.1124/DMD.105.004788 |
P8608 | Fatcat ID | release_odckhoglg5c5rkad7xiiwfa3ua |
P698 | PubMed publication ID | 15919850 |
P50 | author | David J. Waxman | Q30506493 |
P2093 | author name string | Chong-Sheng Chen | |
Youssef Jounaidi | |||
P433 | issue | 9 | |
P921 | main subject | cytotoxicity | Q246181 |
enantioselectivity | Q1339952 | ||
P304 | page(s) | 1261-1267 | |
P577 | publication date | 2005-05-26 | |
P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
P1476 | title | Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. | |
P478 | volume | 33 |
Q91717495 | Antineoplastic Agents: Environmental Prevalence and Adverse Outcomes in Aquatic Organisms |
Q36305439 | Cancer treatment and pharmacogenetics of cytochrome P450 enzymes |
Q24298102 | Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity |
Q39691802 | Comparison of the novel HK-2 human renal proximal tubular cell line with the standard LLC-PK1 cell line in studying drug-induced nephrotoxicity |
Q48199323 | Computationally Assessing the Bioactivation of Drugs by N-Dealkylation. |
Q30520640 | Contributions of human enzymes in carcinogen metabolism |
Q36154879 | Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasma. |
Q37288782 | Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature |
Q28749176 | Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation |
Q37037051 | Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model |
Q39064497 | Enzyme/Prodrug Systems for Cancer Gene Therapy. |
Q47836150 | Establishment and assessment of a novel in vitro bio-PK/PD system in predicting the in vivo pharmacokinetics and pharmacodynamics of cyclophosphamide |
Q36101917 | Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators |
Q37402750 | MicroRNAs regulate CYP3A4 expression via direct and indirect targeting |
Q34113899 | Oxazaphosphorines: new therapeutic strategies for an old class of drugs |
Q39916257 | Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer |
Q97074138 | Prediction and Characterization of CYP3A4-mediated Metabolisms of Azole Fungicides: an Application of the Fused-grid Template* system |
Q35095165 | Prodrugs for improving tumor targetability and efficiency. |
Q51147639 | Screening for biologically annotated drugs that trigger triacylglycerol accumulation in the diatom Phaeodactylum. |
Q49538988 | Significance and challenges of stereoselectivity assessing methods in drug metabolism |
Q47594127 | Stereochemical considerations in pharmacokinetic processes of representative antineoplastic agents |
Q36788391 | Stereoselectivity in drug metabolism |
Q40253486 | Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6. |
Search more.